Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

DVT Prophylaxis After Bunion Surgery for Non-Weightbearing Patients

  • The American College of Physicians recommends enoxaparin 40 mg subcutaneously once daily as the primary pharmacological prophylaxis option for patients after bunion surgery who are non-weightbearing 1, 2
  • Unfractionated heparin (UFH) 5000 IU subcutaneously every 8 hours is an alternative option, particularly for patients with additional VTE risk factors such as cancer 1, 3
  • For patients at high risk of bleeding, mechanical thromboprophylaxis with graduated compression stockings and/or intermittent pneumatic compression (IPC) should be used instead of pharmacological methods 1, 2

Duration of Prophylaxis

  • Pharmacological thromboprophylaxis should be continued throughout the entire non-weightbearing period (6 weeks) 4, 5
  • The majority of VTE events after orthopedic procedures occur after hospital discharge, with approximately 70% occurring within the first month 6, 7

Tapering Considerations

  • Once the patient begins fully weightbearing in the boot, prophylaxis can be discontinued without tapering 1, 2
  • There is no evidence supporting a tapering regimen when transitioning from non-weightbearing to weightbearing status 1, 5
  • The decision to discontinue prophylaxis should coincide with the resumption of full weightbearing, as this significantly reduces the risk of VTE due to increased mobility and muscle pump function 5, 6

Special Population Considerations

  • For patients with renal impairment, UFH is preferred as it's primarily metabolized by the liver, or reduce the dose of enoxaparin to 30 mg subcutaneously once daily 3
  • For obese patients, consider higher doses of enoxaparin or weight-based dosing 6, 7

Clinical Evidence and Rationale

  • Extended duration thromboprophylaxis is particularly important for patients with restricted mobility, as non-weightbearing status is a significant risk factor for VTE 4, 5

Common Pitfalls and Caveats

  • Discontinuing prophylaxis too early, especially before the patient begins weightbearing, which can lead to increased risk of VTE 5
  • Not adjusting dosing for patients with renal impairment or obesity, which can lead to either inadequate protection or increased bleeding risk 3, 6
  • Overlooking the need for extended prophylaxis beyond hospital discharge, as most VTE events occur after patients have left the hospital 4, 6